Literature DB >> 35299116

From tryptophan-based amides to tertiary amines: Optimization of a butyrylcholinesterase inhibitor series.

Anže Meden1, Damijan Knez1, Xavier Brazzolotto2, Florian Nachon2, Jose Dias2, Jurij Svete3, Jure Stojan4, Uroš Grošelj5, Stanislav Gobec6.   

Abstract

Lead optimization of a series of tryptophan-based nanomolar butyrylcholinesterase (BChE) inhibitors led to tertiary amines as highly potent, achiral, sp3-rich analogues with better synthetic accessibility and high selectivity over acetylcholinesterase (one to ten thousandfold). Taking it one step further, the introduction of a carbamate warhead on the well-explored reversible scaffold allowed conversion to pseudoirreversible inhibitors that bound covalently to BChE and prolonged the duration of inhibition (half-life of 14.8 h for compound 45a-carbamoylated enzyme). Additionally, N-hydroxyindole was discovered as a novel leaving group chemotype. The covalent mechanism of action was confirmed by time-dependency experiments, progress curve analysis, and indirectly by co-crystallization with the human recombinant enzyme. Two crystal structures of BChE-inhibitor complexes were solved and coupled with the supporting molecular dynamics simulations increased our understanding of the structure-activity relationship, while also providing the necessary structural information for future optimization of this series. Overall, this research demonstates the high versatility and potential of this series of BChE inhibitors.
Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Butyrylcholinesterase; Carbamate; Cholinesterase inhibitors; Pseudoirreversible inhibition

Mesh:

Substances:

Year:  2022        PMID: 35299116     DOI: 10.1016/j.ejmech.2022.114248

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  1 in total

1.  Screening of Big Pharma's Library against Various in-house Biological Targets.

Authors:  Damijan Knez; Stanislav Gobec; Martina Hrast
Journal:  Molecules       Date:  2022-07-13       Impact factor: 4.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.